Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teikoku Pharma USA, a specialty pharmaceutical company, has signed an exclusive worldwide, licensing agreement with Eisai to develop and commercialize a new transdermal formulation of donepezil, a leading compound for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
According to Teikoku, the transdermal formulation is a once-a-week patch that continuously delivers donepezil through the skin into the bloodstream.
It will enable the number of doses to be reduced, make it easier to be used for patients with Alzheimer’s disease who have difficulty in swallowing, and also reduce the burden of caregivers or family members when administering it to patients, the company said.